Candidiasis, commonly referred to as yeast or fungal infection, is a parasitic disease that naturally exists in the human body. However, certain factors, such as alterations in immune function, can lead to infection. This condition can impact various body parts like the skin, mouth, and gastrointestinal tract. Vaginal yeast infections are prevalent among women and present symptoms like rashes, swelling, redness, stinging, and burning sensations. Contributing factors to yeast infections include weakened immunity, inadequate hygiene practices, and lifestyle-related disorders.
According to Data Bridge Market Research, the Yeast Infection Market accounted for USD 3.88 billion in 2021 and is expected to reach USD 6.23 billion by 2029. The market is expected to grow with a CAGR of 6.10% in the forecast period of 2022 to 2029.
“Growing prevalence of diseases boosts the market’s growth”
The yeast infection market is experiencing growth due to the increasing prevalence of diseases. Various factors contribute to this trend, including the rise in autoimmune diseases, yeast infections, and the emergence of new fungal infections. Additionally, the burden of diseases such as cardiovascular, gastrointestinal and other ailments is on the rise. These conditions create a higher demand for effective treatments, driving the growth of the yeast infection market as healthcare providers and patients seek solutions to manage and treat these infections effectively.
What restraints the growth of the yeast infection market?
“Various treatment related side effects restraints the market’s growth”
Various treatment-related side effects hinder the growth of the yeast infection market. These side effects impose constraints on the market expansion. Patients undergoing treatment for yeast infections often experience adverse reactions such as skin irritation, redness, and itching. Additionally, certain antifungal medications used in treatment can cause gastrointestinal disturbances and allergic reactions. These treatment-related side effects pose challenges and limit the growth potential of the yeast infection market.
Segmentation: Yeast Infection Market
The yeast infection market is segmented on the basis of pathogens, types, treatment, and end user.
- On the basis of pathogens, the yeast infection market has been segmented into candida albicans, candida glabrata, candida rugose, and others.
- On the basis of types, the yeast infection market has been segmented into vaginal yeast infection, skin yeast infection, throat yeast infection, and others.
- On the basis of treatment, the yeast infection market has been segmented into medical treatment and surgery.
- On the basis of end user, the yeast infection market has been segmented into hospital, clinics, ambulatory centers, and others.
Regional Insights: North America dominates the yeast infection market
North America dominates the yeast infection market the prevalence of yeast infections has risen, leading to an increase in vaginal infections reported within the region. This trend indicates a growing problem and highlights the need for attention and appropriate management strategies.
Europe is expected to witness significant growth during the forecast period of 2022 to 2029. The region is witnessing a notable surge in yeast infections, indicating a widespread prevalence of the condition. This high occurrence contributes to its significant impact on the population in that area.
To know more about the study visit, https://www.databridgemarketresearch.com/zh/reports/global-yeast-infection-market
Recent Developments
- In December 2021, Positive topline results from the ReSTORE Phase 3 clinical trial conducted by Cidara Therapeutics, Inc. and Mundipharma were announced. The trial evaluated the safety and effectiveness of rezafungin, an antifungal candidate administered once weekly, as a primary treatment for candidemia and invasive candidiasis.
The Prominent Key Players Operating in the Yeast Infection Market Include:
- Scynexis Inc., (U.S.)
- Merck & Co., Inc. (U.S.)
- Bayer AG (Germany)
- Astellas Pharma Inc., (Japan)
- Thermo Fisher Scientific Inc., (U.S.)
- Novartis AG (Switzerland)
- Abbott (U.S.)
- Catalent, Inc., (U.S.)
- bioMérieux (France)
- Pfizer Inc. (U.S.)
- AbbVie Inc., (U.S.)
- ALLERGAN (Ireland)
- Jubilant Pharmova Limited (India)
- Sanofi (France)
- AstraZeneca (U.K)
- Bruker (U.S.)
- Brundavan Laboratories Ltd. (India)
- Curia Global, Inc. (U.S.)
- Corden Pharma (Germany)
Above are the key players covered in the report, to know about more and exhaustive list of yeast infection market companies contact, https://www.databridgemarketresearch.com/zh/contact
Research Methodology: Global Yeast Infection Market
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
